PreveCeutical Medical (TSE:PREV) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PreveCeutical Medical’s subsidiary, BioGene Therapeutics, appoints Dr. Linnea Olofsson as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer to advance its drug and gene delivery technologies. These strategic appointments are expected to drive innovation and growth in the life sciences sector, positioning the company for future success.
For further insights into TSE:PREV stock, check out TipRanks’ Stock Analysis page.